Syndax Pharmaceuticals (SNDX) Total Debt (2015 - 2026)

Syndax Pharmaceuticals' Total Debt history runs 4 years deep, the most recent figure standing at $343.7 million for Q4 2024.

• In Q4 2024, Total Debt changed N/A year-over-year to $343.7 million; the TTM figure through Dec 2024 stood at $343.7 million (changed N/A YoY), while the FY2024 annual figure was $343.7 million, changed N/A from the prior year.
• Total Debt for Q4 2024 stood at $343.7 million, up from $20.2 million in the prior quarter.
• The five-year high for Total Debt was $343.7 million in Q4 2024, with the low at $19.8 million in Q1 2020.
• The 4-year median for Total Debt is $20.1 million (2020), against an average of $49.5 million.
• Peak annual rise in Total Debt reached 2.36% in 2021, while the deepest fall reached 1.11% in 2021.
• Syndax Pharmaceuticals' Total Debt stood at $20.1 million in 2020, then retreated by 1.11% to $19.9 million in 2021, then increased by 1.56% to $20.2 million in 2022, then jumped by 1600.89% to $343.7 million in 2024.
• Business Quant data shows SNDX's Total Debt at $343.7 million in Q4 2024, $20.2 million in Q2 2022, and $20.0 million in Q1 2022.